9342-8530 Quebec Inc DGCRF

Q4: Little to report

[Dibah42]

Royalties for PCA3 grew by $83k or 14% in Q4 inspite of HOLX's lackadaisical marketing approach.  Total for the year $671k.  Cash on hand $4,190,296 or about $0 .097/ share.
In intense communication with HOLX to buy back the rights but no results to show thus far. In some ways,  IMO, the serious problems HOLX is having may be a plus for CUR in that they might be disposed to make a deal.  Better than an impairment charge.
Not much new to report on GCC. 
CUR (i.e. Fradet?) got an NRC grant for $2-300k to validate a new PC marker.
RB seems to be leaning toward a partnership  with Arun Chinayan of U. Mich and his TMPRS 2/ERG  markers. 
They should be targeting big pharmas which have the $$$ and are hungry for pipeline.
Ho hum

[RetailRube]

Dibah's summary left out one key statement from the earnings conference call.  Freddie (as Dibah calls him) said cash burn in fiscal 2014 could be as high as $2.1 million.  Hence our $4.2 million cash balance at 2013-Oct-31 will shrink to $2.1 million by 2014-Oct-31. Now, we should probably soon set aside $1.3 million just in case we have to lay everyone off and pay them statutory